Also, patients without SVT were more likely to have prescribedloop diuretics (59.6% vs. 27.1%, p < 0.001), mineralocorticoidreceptor antagonists (84.6% vs. 50.0%, p < 0.001), angiotensinreceptor/neprilysin inhibitors (34.6% vs. 8.6%, p < 0.001) andsodium glucose co-transporter 2 inhibitors (44.2% vs. 10.0%, p < 0.001) due to the fact that patients have HF with reduced LVEF and received thetherapy in accordance with the current guidelines for the HF management. This evidence concerns the gene NR3C2 and hydrops fetalis.